Express Pharma
Home  »  Pharma Life  »  Syngene appoints Jonathan Hunt as CEO-designate

Syngene appoints Jonathan Hunt as CEO-designate

4

Hunt will be responsible for strengthening Syngene’s relations with its existing global customers

20160131ep27Syngene International has appointed Jonathan Hunt as CEO-designate. Hunt will take charge as CEO post the retirement of current CEO Peter Bains in March 2016. Bains, who has worked closely with Syngene as a Director since 2010 and was appointed as the CEO in February, 2015 will continue as a member of the Syngene Board post his retirement.

In his new role, Hunt will be responsible for strengthening Syngene’s relations with its existing global customers as well as forging new relationships. He will also steer the company’s investments in developing and strengthening its capabilities and capacities to augment Syngene’s service offerings. Prior to Syngene, Jonathan had a long standing association with Astrazeneca where he held various leadership positions including President & Director of Astrazeneca, Austria and President and Chief Operating Officer, Astrazeneca India. Earlier in his career he worked with Bayer Schering Pharma in various capacities. He holds a BA (Business Studies & Economics) from the University of Sheffield, UK and an MBA from Durham University, UK.

Commenting on the new appointment, Kiran Mazumdar Shaw, Managing Director, Syngene International said, “Hunt has a rich experience in the global biopharma industry and a proven track record of leading transformational change and delivering growth. We are sure, under his leadership, Syngene will continue to strengthen its position in the global CRAMs market.”

Peter Bains, Chief Executive Officer, Syngene International said, “Hunt’s experience in building customer-focused organisations, coupled with his leadership and operational track record, make him the ideal selection for this position and we are delighted to welcome him aboard.”

Hunt said, “I am delighted to be joining Syngene at this exciting point in its journey. Syngene has a compelling business model, a track record of delivering operational excellence to its customers and ambitious plans for continued growth. I look forward to working closely with the Board, senior management team and leading the company to a new phase of growth.”

EP News BureauMumbai

Comments are closed.